What’s in GLOBEIMMUNE INC (OTCMKTS:GBIM) After Rise in Shorted Shares?

GlobeImmune, Inc. (OTCMKTS:GBIM) Logo

The stock of GLOBEIMMUNE INC (OTCMKTS:GBIM) registered an increase of 7.69% in short interest. GBIM’s total short interest was 14,000 shares in August as published by FINRA. Its up 7.69% from 13,000 shares, reported previously. With 700 shares average volume, it will take short sellers 20 days to cover their GBIM’s short positions.

The stock increased 13.22% or $0.0094 during the last trading session, reaching $0.0805. About 4,911 shares traded. GlobeImmune, Inc. (OTCMKTS:GBIM) has 0.00% since August 16, 2018 and is . It has by 0.00% the S&P500.

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. The company has market cap of $2.28 million. The Company’s product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. It currently has negative earnings. The firm is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.